• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's After-Market Session

    4/3/24 4:31:20 PM ET
    $ACOR
    $AIH
    $BOLT
    $CNTB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical Specialities
    Health Care
    Get the next $ACOR alert in real time by email

    Gainers

    • Aesthetic Medical Intl (NASDAQ:AIH) shares rose 14.0% to $0.52 during Wednesday's after-market session. The company's market cap stands at $24.9 million.
    • Kineta (NASDAQ:KA) shares rose 8.46% to $0.58. The company's market cap stands at $6.3 million.
    • Simulations Plus (NASDAQ:SLP) shares increased by 6.74% to $40.99. The market value of their outstanding shares is at $818.4 million. As per the news, the Q2 earnings report came out today.
    • Bolt Biotherapeutics (NASDAQ:BOLT) shares moved upwards by 6.66% to $1.44. The company's market cap stands at $54.9 million.
    • Eiger BioPharmaceuticals (NASDAQ:EIGR) shares increased by 6.66% to $1.76. The market value of their outstanding shares is at $2.6 million.
    • Kodiak Sciences (NASDAQ:KOD) shares rose 5.38% to $4.5. The company's market cap stands at $236.2 million. As per the news, the Q4 earnings report came out 4 days ago.

    Losers

    • Connect Biopharma Hldgs (NASDAQ:CNTB) shares fell 10.8% to $1.9 during Wednesday's after-market session. The company's market cap stands at $104.6 million.
    • Acorda Therapeutics (NASDAQ:ACOR) stock fell 10.4% to $1.81. The market value of their outstanding shares is at $2.2 million. As per the news, the Q4 earnings report came out 2 days ago.
    • Innate Pharma (NASDAQ:IPHA) shares decreased by 8.54% to $2.25. The market value of their outstanding shares is at $181.8 million.
    • Qilian Intl Hldg Gr (NASDAQ:QLI) shares declined by 8.51% to $0.64. The market value of their outstanding shares is at $22.8 million.
    • Universe Pharmaceuticals (NASDAQ:UPC) shares fell 7.33% to $2.53. The company's market cap stands at $9.2 million.
    • Helius Medical Tech (NASDAQ:HSDT) shares declined by 6.33% to $6.07. The company's market cap stands at $5.3 million. As per the press release, Q4 earnings came out 4 days ago. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACOR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACOR
    $AIH
    $BOLT
    $CNTB

    CompanyDatePrice TargetRatingAnalyst
    Innate Pharma S.A. ADS
    $IPHA
    3/12/2026$8.00Buy
    BTIG Research
    Simulations Plus Inc.
    $SLP
    12/18/2025Buy → Neutral
    BTIG Research
    Connect Biopharma Holdings Limited
    $CNTB
    12/1/2025$9.00Buy
    Lake Street
    Kodiak Sciences Inc
    $KOD
    11/11/2025$24.00Neutral → Buy
    H.C. Wainwright
    Connect Biopharma Holdings Limited
    $CNTB
    10/31/2025$10.00Buy
    BTIG Research
    Kodiak Sciences Inc
    $KOD
    10/24/2025$24.00Neutral → Overweight
    Analyst
    Bolt Biotherapeutics Inc.
    $BOLT
    10/20/2025$7.00Buy
    H.C. Wainwright
    Simulations Plus Inc.
    $SLP
    9/30/2025$16.00Hold
    TD Cowen
    More analyst ratings

    $ACOR
    $AIH
    $BOLT
    $CNTB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research resumed coverage on Innate Pharma with a new price target

    BTIG Research resumed coverage of Innate Pharma with a rating of Buy and set a new price target of $8.00

    3/12/26 8:52:58 AM ET
    $IPHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Simulations Plus downgraded by BTIG Research

    BTIG Research downgraded Simulations Plus from Buy to Neutral

    12/18/25 9:02:23 AM ET
    $SLP
    EDP Services
    Technology

    Lake Street initiated coverage on Connect Biopharma with a new price target

    Lake Street initiated coverage of Connect Biopharma with a rating of Buy and set a new price target of $9.00

    12/1/25 9:37:24 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $AIH
    $BOLT
    $CNTB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President, CEO and CFO Quinn William P. bought $576 worth of shares (125 units at $4.61), increasing direct ownership by 6% to 2,313 units (SEC Form 4)

    4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)

    2/4/26 4:32:38 PM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Senior VP, Finance and PAO Nemec Sarah bought $576 worth of shares (125 units at $4.61), increasing direct ownership by 10% to 1,415 units (SEC Form 4)

    4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)

    2/4/26 4:32:00 PM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Baker Bros. Advisors Lp bought $60,000,008 worth of shares (2,608,696 units at $23.00) (SEC Form 4)

    4 - Kodiak Sciences Inc. (0001468748) (Issuer)

    12/19/25 4:06:09 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACOR
    $AIH
    $BOLT
    $CNTB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Innate Pharma to Participate in the Kempen Life Sciences Conference

    Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company"), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that members of its executive team will participate in one-on-one investor meetings at the following conference: Kempen Life Sciences Conference Dates: April 15 –16, 2026 Location: Amsterdam, Netherlands About Innate Pharma Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise on antibody-engineering and innovative target identification, Innate Pharma is developing innovative and differentiated next-ge

    4/3/26 1:00:00 AM ET
    $IPHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Innate Pharma Files Its 2025 Universal Registration Document (Document D'enregistrement Universel) and 2025 Form 20-f Annual Report

    Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today announced the filing of its 2025 Universal Registration Document (Document d'enregistrement universel) for the year ending December 31, 2025 with the French market authority "Autorité des Marchés Financiers" ("AMF") on April 1st, 2026. It can be downloaded (in French) on the Company's website and on the AMF's website. The following documents are incorporated into the Universal Registration Document: the annual financial report, the annual management report, the corporate governance report provided for under Article L. 225-37 of the French Commercial Code, the report of Statutory Audi

    4/2/26 4:00:00 AM ET
    $IPHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

    PALO ALTO, Calif., March 31, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2025. "Kodiak's momentum has continued to build, highlighted by positive Phase 3 topline results from the GLOW2 study and multiple advancing late-stage and pipeline programs that together reinforce the company's differentiated molecules, platform and long term growth strategy," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences."The GLOW2 Phase 3 study delivered strong topline results showing meaningful efficacy, safety and durability of Zenkuda (tarcocimab tedromer) in

    3/31/26 4:45:00 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACOR
    $AIH
    $BOLT
    $CNTB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Borgeson John A.

    4 - Kodiak Sciences Inc. (0001468748) (Issuer)

    4/2/26 8:26:22 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Perkins Sherrie L

    4 - Solana Co (0001610853) (Issuer)

    4/2/26 5:00:33 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Straw Edward M

    4 - Solana Co (0001610853) (Issuer)

    4/2/26 5:00:20 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ACOR
    $AIH
    $BOLT
    $CNTB
    SEC Filings

    View All

    SEC Form 6-K filed by Innate Pharma S.A. ADS

    6-K - Innate Pharma SA (0001598599) (Filer)

    4/3/26 7:02:06 AM ET
    $IPHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Innate Pharma S.A. ADS

    6-K - Innate Pharma SA (0001598599) (Filer)

    4/2/26 6:01:47 AM ET
    $IPHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 20-F filed by Innate Pharma S.A. ADS

    20-F - Innate Pharma SA (0001598599) (Filer)

    4/1/26 6:08:03 AM ET
    $IPHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACOR
    $AIH
    $BOLT
    $CNTB
    Leadership Updates

    Live Leadership Updates

    View All

    Solana Company Executive Chairman's Message: October 20th, 2025

    NEWTOWN, Pa., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Today, Solana Company (NASDAQ:HSDT) released the following letter from the Executive Chairman: We are excited to enter the next phase of our lifecycle with a strong capital base and expanded accessibility for investors. This week will be remembered as a foundational moment for Solana Company (NASDAQ:HSDT). We have made the deliberate choice to move forward with our scheduled registration for resale of the shares purchased by investors in the recent private placement rather than delay it. Whereas some of our peers have decided to postpone it at the first sign of market volatility, we want to explain why we made this decision and why we feel

    10/20/25 10:18:15 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    AppLovin, Robinhood Markets and Emcor Group Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Sept. 5, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 22, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. The companies being removed from the S&P SmallCap 600 are no longer representative of the small-cap market space. Uber Technologies Inc. (NYSE:UBER) will replace Charter Communications Inc. (NASD: CHTR) in the S&P 100. Charter Communications will remain in the S&P 500.AppLovin Corp. (NASD: APP), Robinhood Markets Inc. (NASD: H

    9/5/25 6:34:00 PM ET
    $ACHC
    $APP
    $BGS
    Medical Specialities
    Health Care
    Computer Software: Programming Data Processing
    Technology

    Connect Biopharma Appoints Industry Veteran Jim Schoeneck to its Board of Directors

    – Mr. Schoeneck is a seasoned industry executive and director with deep expertise in development and commercialization of breakthrough products and guiding companies through significant transformation and growth – SAN DIEGO, July 22, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma, Connect, or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced the expansion of the size of its Board of Directors from six to seven directors and the appointment of Jim Schoeneck as a director effective today. "We are pleased to welcome Jim to our Board of Directors," sai

    7/22/25 9:00:00 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $AIH
    $BOLT
    $CNTB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Bolt Biotherapeutics Inc.

    SC 13G/A - Bolt Biotherapeutics, Inc. (0001641281) (Subject)

    11/14/24 4:19:06 PM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Helius Medical Technologies Inc.

    SC 13G/A - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Subject)

    11/8/24 5:12:24 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by Simulations Plus Inc.

    SC 13G/A - Simulations Plus, Inc. (0001023459) (Subject)

    8/8/24 2:18:03 PM ET
    $SLP
    EDP Services
    Technology

    $ACOR
    $AIH
    $BOLT
    $CNTB
    Financials

    Live finance-specific insights

    View All

    Solana Company Reports Fourth Quarter and Full Year 2025 Financial Results

    NEWTOWN, Pa., March 30, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ:HSDT) (the "Company" or "HSDT"), a publicly listed company that has expanded its business to include a digital asset treasury ("DAT") dedicated to acquiring and holding Solana tokens ("SOL"), today announced results for the quarter and full year ended December 31, 2025. Fourth Quarter and Full Year Recent Business Updates Generated $5.1 million in staking rewards in the fourth quarter of 2025 and $5.5 million for the full year, as substantially all SOL holdings were staked throughout the periodRaised $29.9 million in 2025 through the Company's ATM programs, with proceeds used primarily to purchase SOL on an net asse

    3/30/26 4:05:00 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study

    – Rademikibart achieved rapid, durable efficacy results across all key endpoints through 52 weeks, with near‑maximal responses achieved in ~90% of patients – – Rademikibart was well tolerated with safety comparable to placebo – – Data presented during late-breaking oral presentation at 2026 American Academy of Dermatology Annual Meeting –  – Company to host conference call and webcast today, March 30, 2026 at 8:00 a.m. ET – SAN DIEGO, March 30, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today anno

    3/30/26 7:01:00 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD

    – Rademikibart administered as a single 300 mg 2-minute IV push to asthma and chronic obstructive pulmonary disease (COPD) patients produced rapid improvement in FEV1 with many patients experiencing improvements in airway function of ≥200 mL as early as 15 minutes post-dosing – – The rapid improvement in FEV1 demonstrated with IV rademikibart in this study provides clinical confirmation of preclinical observations that rademikibart has a unique beneficial effect on bronchodilation – – Mean FEV1 improvements of ~200 - 400 mL were maintained through Day 29 in asthma and COPD patients – – Recruitment ongoing for Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD;

    3/30/26 7:00:00 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care